In vivo effects of 3,4-methylenedioxymethamphetamine (MDMA) and its deuterated form in rodents: Drug discrimination and thermoregulation.
Berquist, M. D., Leth-Petersen, S., Kristensen, J. L., & Fantegrossi, W. E. | Drug and Alcohol Dependence | 13 January 2020
Antidepressant and neurocognitive effects of serial ketamine administration versus ECT in depressed patients
Basso, L., Bönke, L., Aust, S., Gärtner, M., Heuser-Collier, I., Otte, C., ... & Grimm, S. | Journal of Psychiatric Research | 13 January 2020
A Dangerous Method? Psychedelic Therapy at Modum Bad, Norway, 1961-76
Johnstad, P. G. | History of Psychiatry | 13 January 2020
Ayahuasca’s ‘afterglow’: improved mindfulness and cognitive flexibility in ayahuasca drinkers.
Murphy-Beiner, A., & Soar, K. | Psychopharmacology | 11 January 2020
Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer.
Agin-Liebes, G. I., Malone, T., Yalch, M. M., Mennenga, S. E., Ponté, K. L., Guss, J., ... & Ross, S. | Journal of Psychopharmacology | 9 January 2020
A qualitative descriptive analysis of effects of psychedelic phenethylamines and tryptamine
Palamar, J. J., & Acosta, P. | Clinical and Experimental | 07 January 2020
Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species
Halberstadt, A. L., Chatha, M., Klein, A. K., Wallach, J., & Brandt, S. D. | Neuropharmacology | 7 January 2020
The experimental effects of psilocybin on symptoms of anxiety and depression: A meta-analysis.
Goldberg, S. B., Pace, B. T., Nicholas, C. R., Raison, C. L., & Hutson, P. R. | Psychiatry Research | 2 January 2020
Preliminary Report on the Effects of a Low Dose of LSD on Resting-State Amygdala Functional Connectivity.
Bershad, A. K., Preller, K. H., Lee, R., Keedy, S., Wren-Jarvis, J., Bremmer, M. P., & de Wit, H. | Biological Psychiatry: Cognitive Neuroscience and Neuroimaging | 20 December 2019
Esketamine is approved in Europe for treating resistant major depressive disorder
Mahase, E. | BMJ | 20 December 2019
Lysergic acid diethylamide as an analgesic agent in patients with terminal illnesses
Das, S., & Maiti, T. | PAIN MANAGEMENT | 19 December 2019
Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers.
Family, N., Maillet, E. L., Williams, L. T., Krediet, E., Carhart-Harris, R. L., Williams, T. M., ... & Raz, S. | Psychopharmacology | 18 December 2019
Decreased directed functional connectivity in the psychedelic state.
Barnett, L., Muthukumaraswamy, S. D., Carhart-Harris, R. L., & Seth, A. K. | NeuroImage | 17 December 2019
From Egoism to Ecoism: Psychedelics Increase Nature Relatedness in a State-Mediated and Context-Dependent Manner.
Kettner, H., Gandy, S., Haijen, E. C., & Carhart-Harris, R. L. | International Journal of Environmental Research and Public Health | 16 December 2019
The relationship between subjective effects induced by a single dose of ketamine and treatment response in patients with major depressive disorder: A systematic review.
Mathai, D. S., Meyer, M. J., Storch, E. A., & Kosten, T. R. | Journal of Affective Disorders | 14 December 2019
Neurotrophic mechanisms of psychedelic therapy
Corne, R., & Mongeau, R. | Biologie aujourd'hui | 12 December 2019
Neurochemical and Behavioral Profiling in Male and Female Rats of the Psychedelic Agent 25I-NBOMe
Miliano, C., Marti, M., Pintori, N., Castelli, M. P., Tirri, M., Arfè, R., & De Luca, M. A. | Frontiers in Pharmacology | 12 December 2019
Prospective examination of synthetic 5-methoxy-N,N-dimethyltryptamine inhalation: effects on salivary IL-6, cortisol levels, affect, and non-judgment
Uthaug, M. V., Lancelotta, R., Szabo, A., Davis, A. K., Riba, J., & Ramaekers, J. G. | Psychopharmacology | 10 December 2019
Neuropharmacological modulation of the aberrant bodily self through psychedelics
Ho, J. T., Preller, K. H., & Lenggenhager, B. | Neuroscience & Biobehavioral Reviews | 6 December 2019
Modulation of Social Cognition via Hallucinogens and “Entactogens”.
Preller, K. H., & Vollenweider, F. X. | Frontiers in Psychiatry | 3 December 2019
Therapeutic use of serotoninergic hallucinogens: A review of the evidence and of the biological and psychological mechanisms.
dos Santos, R. G., & Hallak, J. E. C. | Neuroscience & Biobehavioral Reviews | 3 December 2019
Embedding existential psychology within psychedelic science: reduced death anxiety as a mediator of the therapeutic effects of psychedelics.
Moreton, S. G., Szalla, L., Menzies, R. E., & Arena, A. F. | Psychopharmacology | 29 November 2019
Twenty percent better with 20 micrograms? A qualitative study of psychedelic microdosing self-rapports and discussions on YouTube.
Andersson, M., & Kjellgren, A. | Harm reduction journal | 28 November 2019
Microdosing psychedelics: Motivations, subjective effects and harm reduction.
Lea, T., Amada, N., Jungaberle, H., Schecke, H., & Klein, M. | International Journal of Drug Policy | 25 November 2019
Psilocybin-assisted therapy for depression: How do we advance the field?
Meikle, S. E., Liknaitzky, P., Rossell, S. L., Ross, M., Strauss, N., Thomas, N., ... & Castle, D. J. | Australian & New Zealand Journal of Psychiatry | 22 November 2019